Compare HHS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HHS | MRKR |
|---|---|---|
| Founded | 1923 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 19.5M |
| IPO Year | 1994 | 2010 |
| Metric | HHS | MRKR |
|---|---|---|
| Price | $4.52 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.87 |
| AVG Volume (30 Days) | ★ 94.9K | 64.1K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | 33.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,570,000.00 | N/A |
| Revenue This Year | N/A | $19.61 |
| Revenue Next Year | N/A | $375.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.00 | $0.84 |
| 52 Week High | $4.67 | $2.46 |
| Indicator | HHS | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 65.97 | 37.42 |
| Support Level | $4.14 | $1.08 |
| Resistance Level | N/A | $1.31 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 74.42 | 4.17 |
Harte-Hanks Inc is a customer experience company. The company operates three business segments: Revenue Solutions; Customer Care; and Fulfillment & Logistics Services. It derives maximum revenue from Fulfillment & Logistics Services segment. The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, monitoring and tracking, to support traditional and specialized mailings. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).